Equities

Aarey Drugs and Pharmaceuticals Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
AAREYDRUGS:NSI

Aarey Drugs and Pharmaceuticals Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)66.42
  • Today's Change0.17 / 0.26%
  • Shares traded73.92k
  • 1 Year change+50.61%
  • Beta1.7498
Data delayed at least 15 minutes, as of Feb 16 2026 10:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Aarey Drugs and Pharmaceuticals Limited is an India-based company, which is engaged in the manufacturing and trading of drugs and pharmaceuticals. The Company is in active pharmaceutical ingredients (API)/bulk drug manufacturing and offers a range of products for various industrial applications. Its products include N-Methyl Urea, Mefenamic acid, Doxofylline, Lumefantrine, Nimesulide, Albendazole, Carbamazepine and Oxcarbazepine. The Company's chemical and solvents include Aeromatics Chemical, Chemical acid, Chlor Alkali, Industrial Alchols, Industrial Ketones, Glycols and Glycol Ethers, Fiber Intermediates, Industrial Amines, Acetates and Esters, Industrial Oleochemicals, Industrial Intermediates, Chlorinated Solvents, Industrial Olefines, Industrial Phosphates, Industrial Fertilizers, Industrial Monomers and Industrial Chemicals. Its chemical acid products include Acetic acid, Citric acid, Formic acid and Hydrochloric acid.

  • Revenue in INR (TTM)3.91bn
  • Net income in INR34.35m
  • Incorporated1990
  • Employees0.00
  • Location
    Aarey Drugs and Pharmaceuticals Ltd107, Sahakar Bhavan340/348, Narshi Natha Street, MasjidMUMBAI 400009IndiaIND
  • Phone+91 2 262872900
  • Fax+91 2 266313166
  • Websitehttp://www.aareydrugs.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Natural Capsules Ltd1.80bn-119.43m1.72bn171.00--0.757164.010.9546-11.49-11.49178.14219.250.43613.902.8510,514,820.00-2.903.87-4.045.4848.2942.06-6.646.390.9601-0.58470.3136--8.8722.41-88.88-6.3653.13--
Aarey Drugs and Pharmaceuticals Ltd3.91bn34.35m1.90bn0.0055.81--32.470.48591.201.20136.13------------1.94--4.311.693.380.87871.20---0.8387----19.809.57-14.09-7.0341.47--
Quest Laboratories Ltd1.10bn136.79m2.11bn50.0015.422.3414.611.918.348.3467.1554.880.89143.333.6022,028,980.0011.07--15.63--14.94--12.42--2.046.810.2672--25.92--34.40------
Brooks Laboratories Ltd888.46m216.03m2.23bn323.0010.36--9.642.517.327.3230.45--------2,750,638.00---14.21---23.3938.7525.9924.31-25.22--------3.863.4549.13---18.61--
Vaidya Sane Ayurved Laboratories Ltd979.90m87.17m2.27bn636.0027.943.3516.292.327.737.7385.7664.411.274.6215.21--11.327.0413.259.5283.8473.318.914.292.3284.890.0092---9.553.61260.35--17.02--
Sat Kartar Life Ltd-100.00bn-100.00bn2.29bn922.00--------------------------21.07--34.79--93.36--4.50------5.3927.3756.3155.66117.3339.27--
Data as of Feb 16 2026. Currency figures normalised to Aarey Drugs and Pharmaceuticals Ltd's reporting currency: Indian Rupee INR
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.